Blackrock Neurotech Announces Expansion of MoveAgain BCI System Clinical Program
Summary
Blackrock Neurotech announced the expansion of its MoveAgain BCI system clinical program to additional medical centers across the United States. The MoveAgain system uses the company's Neuropixel array technology to enable patients with paralysis to control digital devices with their thoughts. The expansion aims to enroll a larger and more diverse patient population.
Why it matters
The expansion of Blackrock's clinical program increases access to one of the most advanced investigational BCI systems for patients with severe paralysis. With more than two decades of BCI research experience, Blackrock brings significant expertise to the growing field of implanted neural interfaces. The expanded program will generate more comprehensive data on BCI safety and effectiveness across different patient populations and use cases.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial